Prot #CA209-76K: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma.

  • Sosman, Jeffrey Alan (PD/PI)

Project: Research project

Project Details

StatusActive
Effective start/end date7/1/20 → 7/1/26

Funding

  • Bristol-Myers Squibb Company ((OE) Prot #CA209-76K)